OncoMatch/Clinical Trials/NCT05870423
Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors
Is NCT05870423 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies olaparib for neuroendocrine tumors.
Treatment: olaparib — This is a phase 1 dose-escalation study to determine the maximum tolerated dose of the PARP inhibitor olaparib in combination with PRRT in patients with a well-differentiated advanced gastroenteropancreatic NET (GEP NET), progressive after PRRT. As secondary objectives, efficacy, pharmacokinetics and biomarker response will be investigated.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Disease stage
Grade: 123
Prior therapy
Must have received: peptide receptor radionuclide therapy (177Lu-DOTATATE) — initial or salvage
Disease progression based on RECIST v1.1 following initial or salvage treatment with PRRT with 177Lu-DOTATATE
Cannot have received: surgery
Exception: within 12 weeks prior to inclusion
Any surgery...within 12 weeks prior to inclusion in the study.
Cannot have received: radioembolization
Exception: within 12 weeks prior to inclusion
radioembolization...within 12 weeks prior to inclusion in the study.
Cannot have received: chemoembolization
Exception: within 12 weeks prior to inclusion
chemoembolization...within 12 weeks prior to inclusion in the study.
Cannot have received: chemotherapy
Exception: within 12 weeks prior to inclusion
chemotherapy...within 12 weeks prior to inclusion in the study.
Cannot have received: radiofrequency ablation
Exception: within 12 weeks prior to inclusion
radiofrequency ablation within 12 weeks prior to inclusion in the study.
Cannot have received: interferon (interferons)
Exception: within 4 weeks prior to inclusion
Interferons...within 4 weeks prior to inclusion in the study.
Cannot have received: mTOR inhibitor (everolimus)
Exception: within 4 weeks prior to inclusion
everolimus...within 4 weeks prior to inclusion in the study.
Cannot have received: VEGFR inhibitor (sunitinib)
Exception: within 4 weeks prior to inclusion
sunitinib...within 4 weeks prior to inclusion in the study.
Cannot have received: systemic therapy
Exception: within 4 weeks prior to inclusion
other systemic therapies within 4 weeks prior to inclusion in the study.
Cannot have received: external beam radiation therapy
Exception: to more than 25% of the bone marrow
Prior external beam radiation therapy to more than 25% of the bone marrow.
Lab requirements
Blood counts
Hb concentration <6.2 mmol/L; white blood cell count <3x10^9/L; platelets <100x10^9/L; neutrophil count <1.5x10^9/L
Kidney function
creatinine clearance <50 mL/min, measured in 24-hour urine collection
Liver function
total bilirubin >3 x ULN, ALT or AST > 2.5 x ULN or serum albumin <3.0 g/dL unless prothrombin time is within the normal range
Cardiac function
Uncontrolled congestive heart failure (NYHA II, III, IV) [excluded]
Hb concentration <6.2 mmol/L; white blood cell count <3x10^9/L; platelets <100x10^9/L; neutrophil count <1.5x10^9/L. Renal insufficiency defined as a creatinine clearance <50 mL/min, measured in 24-hour urine collection. Liver function or enzyme abnormalities defined as a total bilirubin >3 x ULN, Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x ULN or serum albumin <3.0 g/dL unless prothrombin time is within the normal range. Uncontrolled congestive heart failure (NYHA II, III, IV) [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify